Contemporary diagnostic approach to arrhythmogenic cardiomyopathy: The three-step work-up
Francesca Graziano1, Alessandro Zorzi2, Alberto Cipriani2
1Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy; Department of Sports Medicine, Semmelweis University, Budapest, Hungary; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Insights
Diagnosing Arrhythmogenic Cardiomyopathy (ACM) has evolved significantly. Recent European Task Force criteria (2023) improve detection by incorporating left ventricular disease and cardiac MRI findings, advancing ACM diagnosis.
Area of Science:
- Cardiology
- Genetics
- Medical Diagnostics
Background:
- Arrhythmogenic Cardiomyopathy (ACM) is a genetic heart disorder causing myocardial scarring, electrical instability, and potential heart failure.
- Diagnosing ACM is complex due to the absence of a single definitive test, necessitating a multi-faceted approach.
Purpose of the Study:
- To review the 20-year evolution of diagnostic criteria for Arrhythmogenic Cardiomyopathy.
- To highlight advancements in understanding ACM pathobiology and morpho-functional features.
Main Methods:
- Review of diagnostic criteria from 1994 to 2023.
- Analysis of the progression from right ventricular focus to comprehensive assessment including left ventricular variants.
- Inclusion of cardiac magnetic resonance imaging (CMR) tissue characterization in diagnostic frameworks.
Main Results:
- Initial criteria (1994, 2010) focused on right ventricular abnormalities.
- The 2020 Padua criteria expanded diagnosis to include left ventricular ACM and CMR findings.
- The 2023 European Task Force criteria represent a refined, internationally recognized standard for ACM diagnosis.
Conclusions:
- Diagnostic criteria for ACM have progressively improved over two decades.
- Modern criteria, like the 2023 European Task Force guidelines, offer enhanced accuracy and broader applicability.
- These advancements reflect a deeper understanding of ACM's complex pathology.
Abstract:
Arrhythmogenic Cardiomyopathy (ACM) is a cardiac disorder characterized by non-ischemic myocardial scarring, which may lead to ventricular electrical instability and systolic dysfunction. Diagnosing ACM is challenging as there is no single gold-standard test and a combination of criteria is required. The first diagnostic criteria were established in 1994 and revised in 2010, focusing primarily on right ventricular involvement. However, in 2019, an international expert report identified limitations of previous diagnostic scoring and developed the 2020 Padua criteria with also included criteria for diagnosis of left ventricular variants and introduced cardiac magnetic resonance tissue characterization findings for detection of left ventricular myocardial scar. These criteria were further refined and published in 2023 as the European Task Force criteria, gaining international recognition. This review provides an overview of the 20 years of progresses on the disease diagnostic from the original 1994 criteria to the most recent 2023 European criteria, highlighting the evolution into our understanding of the pathobiology and morpho-functional features of the disease.
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
Acute Coronary Syndrome III: Diagnostic studies
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis II: Clinical features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy


